Skip to main content
. 2017 Mar 9;9:17. doi: 10.1186/s13195-017-0245-y

Fig. 1.

Fig. 1

cGMP, but not cAMP, levels in CSF of AD patients are reduced. Box plots comparing CSF levels of cGMP (a) and cAMP (b) in CSF of patients with AD compared with control patients measured by ELISA. (a) cGMP levels in the CSF of AD patients were significantly reduced compared with control subjects (p = 0.017). (b) cAMP levels in the CSF of AD patients were not altered. Mann–Whitney U test. AD Alzheimer’s disease, cAMP cyclic adenosine-3',5'-monophosphate, cGMP cyclic guanosine-3',5'-monophosphate, CSF cerebrospinal fluid